Taysha Gene Therapies Grants 349,000 Restricted Stock Units to New Employees
Taysha Gene Therapies announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units representing 349,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date.
Trade with 70% Backtested Accuracy
Analyst Views on TSHA
About TSHA
About the author
Taysha Gene Therapies Doses First Patient in TSHA-102 Pivotal Trial for Rett Syndrome
- Trial Progress: Taysha Gene Therapies successfully dosed the first patient in the TSHA-102 pivotal trial in Q4 2025, with plans to complete dosing for all 15 patients by Q2 2026, marking a significant milestone in the treatment of Rett syndrome.
- FDA Alignment: The company reached written alignment with the FDA to include three months of safety data from the ASPIRE trial in its planned BLA submission, aiming to enable broad labeling for patients aged two and older, which will expedite the path to market.
- Market Opportunity: With an estimated 15,000 to 20,000 patients affected by Rett syndrome across the U.S., EU, and U.K., Taysha aims to redefine the treatment paradigm for this high unmet need disease through compelling clinical data from TSHA-102, presenting a significant market opportunity.
- Long-term Data Update: An update on long-term safety and efficacy data from the REVEAL trial is expected in H1 2026, which will provide crucial support for the company's future treatment strategies and enhance its competitive position in the market.
Taysha Grants 212,000 Stock Options to New Employees
- Employee Incentive Program: On December 3, 2025, Taysha Gene Therapies granted 212,000 stock options to two new employees at an exercise price of $4.49 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the gene therapy sector.
- Option Structure: These options will be valid for 10 years and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the subsequent 36 months, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in talent acquisition, which can bolster investor confidence.
- Strategic Goals: Taysha focuses on developing gene therapies for severe monogenic diseases, particularly its clinical program TSHA-102 for Rett syndrome, and aims to accelerate research and development through these incentive measures to address unmet medical needs.
Goldman Sachs Upgrades Taysha Gene Therapies Due to Progress in Rett Syndrome Treatment
Goldman Sachs Upgrade: Goldman Sachs has upgraded Taysha Gene Therapies (TSHA) to a buy rating, citing progress with its Rett syndrome candidate TSHA-102, which has moved into phase 3 trials.
Price Target and Market Potential: The investment bank set a price target of $11, indicating a potential upside of approximately 145%, and estimates global peak sales for TSHA-102 could reach $3 billion.
Positive Analyst Outlook: Analyst Salveen Richter expressed optimism about the late-stage trial results, noting that TSHA-102 is differentiated from competitor Neurogene's gene therapy based on clinical and safety data.
Recent Stock Performance: Taysha's stock has seen an increase of about 11% in trading, reflecting positive market sentiment following the upgrade and developments in their clinical trials.
Insider at Taysha Gene Therapies Sells Shares Valued at $1,695,906, Recent SEC Filing Reveals
Leadership Role: Sukumar Nagendran serves as the Director, President, and Head of Research & Development.
Date of Announcement: The information was shared on November 28, 2025.
"Invest in Taysha Gene Therapies at $2.50 and Achieve 24% Returns with Options"
Put Selling and Upside Potential: Selling a put option on Taysha Gene Therapies Inc does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which depends on the stock price falling significantly.
Counterparty Risk and Myths: The article discusses common myths about options, including counterparty risk, emphasizing that the put seller's only benefit is the premium collected unless the stock price drops enough to warrant exercising the option.
Volatility and Trading History: The historical volatility of Taysha Gene Therapies Inc is noted to be 98%, which, along with the stock's trading history, can help assess the risk-reward balance of selling the December 2026 put option at a $2.50 strike price.
Investment Considerations: Investors are encouraged to analyze both the stock's historical performance and fundamental factors when considering the potential return of 21.8% annualized from selling the put option.
Raymond James Begins Coverage of Taysha Gene Therapies with a Strong Buy Rating and Sets Price Target at $13
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
Taysha Gene Therapies Doses First Patient in TSHA-102 Pivotal Trial for Rett Syndrome
- Trial Progress: Taysha Gene Therapies successfully dosed the first patient in the TSHA-102 pivotal trial in Q4 2025, with plans to complete dosing for all 15 patients by Q2 2026, marking a significant milestone in the treatment of Rett syndrome.
- FDA Alignment: The company reached written alignment with the FDA to include three months of safety data from the ASPIRE trial in its planned BLA submission, aiming to enable broad labeling for patients aged two and older, which will expedite the path to market.
- Market Opportunity: With an estimated 15,000 to 20,000 patients affected by Rett syndrome across the U.S., EU, and U.K., Taysha aims to redefine the treatment paradigm for this high unmet need disease through compelling clinical data from TSHA-102, presenting a significant market opportunity.
- Long-term Data Update: An update on long-term safety and efficacy data from the REVEAL trial is expected in H1 2026, which will provide crucial support for the company's future treatment strategies and enhance its competitive position in the market.
Taysha Grants 212,000 Stock Options to New Employees
- Employee Incentive Program: On December 3, 2025, Taysha Gene Therapies granted 212,000 stock options to two new employees at an exercise price of $4.49 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the gene therapy sector.
- Option Structure: These options will be valid for 10 years and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the subsequent 36 months, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in talent acquisition, which can bolster investor confidence.
- Strategic Goals: Taysha focuses on developing gene therapies for severe monogenic diseases, particularly its clinical program TSHA-102 for Rett syndrome, and aims to accelerate research and development through these incentive measures to address unmet medical needs.
Goldman Sachs Upgrades Taysha Gene Therapies Due to Progress in Rett Syndrome Treatment
Goldman Sachs Upgrade: Goldman Sachs has upgraded Taysha Gene Therapies (TSHA) to a buy rating, citing progress with its Rett syndrome candidate TSHA-102, which has moved into phase 3 trials.
Price Target and Market Potential: The investment bank set a price target of $11, indicating a potential upside of approximately 145%, and estimates global peak sales for TSHA-102 could reach $3 billion.
Positive Analyst Outlook: Analyst Salveen Richter expressed optimism about the late-stage trial results, noting that TSHA-102 is differentiated from competitor Neurogene's gene therapy based on clinical and safety data.
Recent Stock Performance: Taysha's stock has seen an increase of about 11% in trading, reflecting positive market sentiment following the upgrade and developments in their clinical trials.
Insider at Taysha Gene Therapies Sells Shares Valued at $1,695,906, Recent SEC Filing Reveals
Leadership Role: Sukumar Nagendran serves as the Director, President, and Head of Research & Development.
Date of Announcement: The information was shared on November 28, 2025.
"Invest in Taysha Gene Therapies at $2.50 and Achieve 24% Returns with Options"
Put Selling and Upside Potential: Selling a put option on Taysha Gene Therapies Inc does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which depends on the stock price falling significantly.
Counterparty Risk and Myths: The article discusses common myths about options, including counterparty risk, emphasizing that the put seller's only benefit is the premium collected unless the stock price drops enough to warrant exercising the option.
Volatility and Trading History: The historical volatility of Taysha Gene Therapies Inc is noted to be 98%, which, along with the stock's trading history, can help assess the risk-reward balance of selling the December 2026 put option at a $2.50 strike price.
Investment Considerations: Investors are encouraged to analyze both the stock's historical performance and fundamental factors when considering the potential return of 21.8% annualized from selling the put option.
Raymond James Begins Coverage of Taysha Gene Therapies with a Strong Buy Rating and Sets Price Target at $13
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
